Show simple item record

dc.contributor.authorBorg, DJ
dc.contributor.authorWang, R
dc.contributor.authorMurray, L
dc.contributor.authorTong, H
dc.contributor.authorSteptoe, RJ
dc.contributor.authorMcGuckin, MA
dc.contributor.authorHasnain, SZ
dc.date.accessioned2020-12-18T03:08:31Z
dc.date.available2020-12-18T03:08:31Z
dc.date.issued2017-11-01
dc.identifierpii: 10.1007/s00125-017-4392-2
dc.identifier.citationBorg, D. J., Wang, R., Murray, L., Tong, H., Steptoe, R. J., McGuckin, M. A. & Hasnain, S. Z. (2017). The effect of interleukin-22 treatment on autoimmune diabetes in the NOD mouse. DIABETOLOGIA, 60 (11), pp.2256-2261. https://doi.org/10.1007/s00125-017-4392-2.
dc.identifier.issn0012-186X
dc.identifier.urihttp://hdl.handle.net/11343/255647
dc.description.abstractAIMS/HYPOTHESIS: The aim of this study was to determine whether therapy with the cytokine IL-22 could be used to prevent the development of, or treat, autoimmune diabetes in the NOD mouse. METHODS: Six-week-old NOD mice were administered bi-weekly either recombinant mouse IL-22 (200 ng/g) or PBS (vehicle control) intraperitoneally until overt diabetes was diagnosed as two consecutive measurements of non-fasting blood glucose ≥ 11 mmol/l. At this time, NOD mice in the control arm were treated with LinBit insulin pellets and randomised to bi-weekly therapeutic injections of either PBS or IL-22 (200 ng/g) and followed until overt diabetes was diagnosed, as defined above. RESULTS: IL-22 therapy did not delay the onset of diabetes in comparison with the vehicle-treated mice. We did not observe an improvement in islet area, glycaemic control, beta cell residual function, endoplasmic reticulum stress, insulitis or macrophage and neutrophil infiltration as determined by non-fasting blood glucose, C-peptide and histological scoring. Therapeutic administration of IL-22 did not reduce circulating lipopolysaccharide, a marker of impaired gut mucosal integrity. CONCLUSIONS/INTERPRETATION: Our study suggests that, at this dosing regimen introduced either prior to overt diabetes or at diagnosis of diabetes, recombinant mouse IL-22 therapy cannot prevent autoimmune diabetes, or prolong the honeymoon period in the NOD mouse.
dc.languageEnglish
dc.publisherSPRINGER
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleThe effect of interleukin-22 treatment on autoimmune diabetes in the NOD mouse
dc.typeJournal Article
dc.identifier.doi10.1007/s00125-017-4392-2
melbourne.affiliation.departmentMedicine Dentistry & Health Sciences
melbourne.source.titleDiabetologia
melbourne.source.volume60
melbourne.source.issue11
melbourne.source.pages2256-2261
dc.rights.licenseCC BY
melbourne.elementsid1290863
melbourne.contributor.authorMcGuckin, Michael
dc.identifier.eissn1432-0428
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record